A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Long-Term Safety of Alvimopan 0.5mg Twice Daily for 12 Months for the Treatment of Opoid Induced Bowel Dysfunction in Adults Taking Opoid Therapy for Persistent Non-Cancer Pain